Fexagratinib

DB12247InvestigationalSmall molecule

AZD4547 has been used in trials studying the treatment of Cancer, LYMPHOMA, Gastric Cancer, Adenocarcinoma, and Solid Neoplasm, among others.

Mechanism: Pharmacologically active on Fibroblast growth factor receptor 1 and Fibroblast growth factor receptor
Curator reviewed
Formula / weight: C₂₆H₃₃N₅O₃ · 463.582 g/mol (avg)
Also known as: N-(5-(2-(3,5-DIMETHOXYPHENYL)ETHYL)-1H-PYRAZOL-3-YL)-4-((3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE

Resolves to

Compound

Structure

InChIKeyVRQMAABPASPXMW-HDICACEKSA-NSMILESCOC1=CC(OC)=CC(CCC2=CC(NC(=O)C3=CC=C(C=C3)N3C[C@H](C)N[C@H](C)C3)=NN2)=C1

Targets

What you can answer from here — as of September 16, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fexagratinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.